Alpha 2.0
Login Register
» Authors » Carmen Munoz-Villafranca

Carmen Munoz-Villafranca

Explore the profile of Carmen Munoz-Villafranca including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 33
Followers 0
Related Specialties
Gastroenterology
General Medicine
Biochemistry
Top 10 Co-Authors
Ana Gutierrez
Cristina Rodriguez
Olga Merino
Javier P Gisbert
Fernando Bermejo
Eugeni Domenech
Luis Fernandez-Salazar
Blau Camps
Luis Bujanda
Jesus Barrio
Published In
Rev Esp Enferm Dig
Front Med (Lausanne)
Dig Liver Dis
Int J Mol Sci
J Crohns Colitis
Affiliations
Soon will be listed here.
Recent Articles
1.
Persistence, Effectiveness, and Safety of Upadacitinib in Crohn's Disease and Ulcerative Colitis in Real Life: Results From a Spanish Nationwide Study (Ureal Study)
Garcia M, Brenes Y, Vicuna M, Bermejo F, Sierra-Ausin M, Vicente R, et al.
Am J Gastroenterol . 2024 Nov; PMID: 39588977
Introduction: Real-world data on the effectiveness of upadacitinib for inflammatory bowel disease (IBD) are limited. To assess upadacitinib persistence, effectiveness, and safety in a real-world scenario. Methods: Retrospective multicenter study...
2.
Inflammatory Bowel Disease: A Comprehensive Analysis of Molecular Bases, Predictive Biomarkers, Diagnostic Methods, and Therapeutic Options
Diez-Martin E, Hernandez-Suarez L, Munoz-Villafranca C, Martin-Souto L, Astigarraga E, Ramirez-Garcia A, et al.
Int J Mol Sci . 2024 Jul; 25(13). PMID: 39000169
In inflammatory bowel diseases (IBDs), such as Crohn's disease (CD) and ulcerative colitis (UC), the immune system relentlessly attacks intestinal cells, causing recurrent tissue damage over the lifetime of patients....
3.
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
Gutierrez A, Zapater P, Ricart E, Gonzalez-Vivo M, Gordillo J, Olivares D, et al.
Front Med (Lausanne) . 2022 Feb; 9:823900. PMID: 35178413
Background: Previous studies comparing immigrant ethnic groups and native patients with IBD have yielded clinical and phenotypic differences. To date, no study has focused on the immigrant IBD population in...
4.
Ustekinumab treatment for toxic megacolon in severe colonic Crohn's disease
Irabien M, Arreba P, Ortiz de Zarate J, Hernandez-Aretxabaleta N, de la Maza-Ortiz S, Ispizua-Madariaga N, et al.
Rev Esp Enferm Dig . 2020 Nov; 113(3):189-192. PMID: 33244975
Toxic megacolon is most commonly considered as a complication of inflammatory bowel disease, especially ulcerative colitis and colonic Crohn's disease to a lesser extent. It appears in the context of...
5.
Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study
Guerra I, Bujanda L, Castro J, Merino O, Tosca J, Camps B, et al.
J Crohns Colitis . 2019 May; 13(12):1492-1500. PMID: 31063540
Background And Aims: Primary sclerosing cholangitis [PSC] is usually associated with inflammatory bowel disease [IBD]. An increased risk of malignancies, mainly colorectal cancer [CRC] and cholangiocarcinoma [CCA], has been reported...
6.
Adalimumab treatment of anti-TNF-naïve patients with ulcerative colitis: Deep remission and response factors
Munoz-Villafranca C, Ortiz de Zarate J, Arreba P, Higuera R, Gomez L, Ibanez S, et al.
Dig Liver Dis . 2018 Apr; 50(8):812-819. PMID: 29625907
Background: Adalimumab is the second tumour necrosis factor antagonist (anti-TNF) adopted for the treatment of ulcerative colitis. Clinical data from naïve patients are scarce. Aim: Examine the response to adalimumab...
7.
Pseudoaneurysm of the cystic artery: An uncommon cause of upper gastrointestinal bleeding in a case of xanthogranulomatous cholecystitis
Munoz-Villafranca C, Garcia-Kamirruaga I, Gome-Garcia P, Atin-del-Campo V, Barcena-Robredo V, Aguinaga-Alesanco A, et al.
Rev Esp Enferm Dig . 2015 Jun; 107(6):375-6. PMID: 26031867
No abstract available.